Loading stock data…
$54.45+0.10 (+0.19%)
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TG Therapeutics, Inc. in the Healthcare sector is trading at $54.45 with a market capitalization of $8.3B. Wall Street consensus targets $69.71 (7 analysts), implying a +28.0% move over the next 12 months. The stock is currently near its 52-week high of $59.30, remaining 28.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $240.34M↑ | $204.92M↑ | $192.57M↑ | $161.71M↑ | $141.15M |
| Gross Profit | $199.14M↑ | $171.41M↑ | $154.43M↑ | $133.62M↑ | $122.21M |
| Operating Income | $21.67M↓ | $34.80M↓ | $50.49M↑ | $29.36M↓ | $34.84M |
| Net Income | $7.78M↓ | $19.78M↓ | $23.04M↓ | $390.89M↑ | $28.19M |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMV...